Tweets
ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI?
https://t.co/J4aE4jxNb0 https://t.co/b6axwp4Tuw
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update
https://t.co/iccSFuAogX https://t.co/ORzwvDKqVo
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes
https://t.co/46g8ek286u https://t.co/FEFq4vkiPk
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
ICYMI: 9 Facts about Leflunomide
Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui.
https://t.co/WseVa589Fg. https://t.co/K4u00MbwEb
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
ICYMI: JAMA: SLE Review
https://t.co/GJJSOYZru2 https://t.co/mCgWy27yPr
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
ICYMI: BSR Guideline on Management of Sjogren’s Syndrome
https://t.co/MMG3NmCeDl https://t.co/zKlR8jOkLD
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Review of Amyloidosis
The New England Journal of Medicine has published a review of systemic amyloidosis.
https://t.co/qtbdPrlKnj https://t.co/wcqvRAauWC
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127, "PREDICTING PERSISTENT INFLAMMATORY ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM: DEVELOPMENT OF SCORES FOR RISK STRATIFICATION", at Eular 2024 in Vienna, Austria.
https://t.co/Yzr9feNjjF https://t.co/BKVbDv3e4E
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis
An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA)
https://t.co/JjhkQM672t. https://t.co/dM25kIcC26
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
RT @drdavidliew I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial.
Would love to eventually see:
- H2H comparative effect vs toci, secukinumab
- structural outcomes
- long-term safety
#EULAR2024
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
RT @yuz6yusof
#EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.
#EULAR2024
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
